Loading...
Loading...
In a report published Wednesday, Canaccord Genuity analyst John Newman initiated coverage on
Regeneron PharmaceuticalsREGN with a Buy rating and $350.00 price target.
In the report, Canaccord Genuity noted, “We are initiating coverage of Regeneron with a BUY rating and $350 price target. Regeneron has the top pipeline in biotech, in our view, with two Phase 3 validated drugs in development, and an additional Phase 2 validated asset. We expect continued pipeline success to drive long-term growth going forward.”
Regeneron Pharmaceuticals closed on Tuesday at $288.08.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in